GO
Loading...

Enter multiple symbols separated by commas

Pfizer Inc

More

  • BASEL, Switzerland, June 29- Drugmakers said on Monday they would continue to ship medicines to Greece in coming weeks, despite mounting unpaid bills, but warned supplies could be in jeopardy if Europe did not take emergency action. A copy of the letter to EU Health Commissioner Vytenis Andriukaitis from Richard Bergstrom, director general of the European...

  • June 26- Drug developer Celladon Corp said on Friday it may liquidate itself if it were unable to find a buyer, and was suspending development of its gene therapy for heart failure. Celladon said if it were to liquidate during the third quarter ending September, the net cash available for distribution to shareholders would be about $25 million- $30 million.

  • June 25- Canada- based drugmaker Valeant Pharmaceuticals International Inc has approached to buy Zoetis Inc, an animal-health company, the Wall Street Journal reported. Shares of Zoetis, whose pipeline includes medicines and vaccines for pets and livestock, were up 2 percent at $56.65 in extended trading. The decision came a month after Bill Ackman's Pershing...

  • Valeant offers to buy Zoetis - WSJ Thursday, 25 Jun 2015 | 4:30 PM ET

    June 25- Canada- based drugmaker Valeant Pharmaceuticals International Inc has approached to buy Zoetis Inc, an animal-health company, the Wall Street Journal reported. Zoetis, spun off from Pfizer Inc in 2013, was valued at $24.85 billion as of Thursday's close, according to Thomson Reuters data. It was not clear what Zoetis's reaction to the approach was, if any,...

  • Panel gives weak endorsement of new meningitis shots Wednesday, 24 Jun 2015 | 12:44 PM ET

    NEW YORK— A federal panel gave a weak endorsement Wednesday to two expensive meningitis shots, declining to recommend that all teens get the vaccine and leaving the decision to parents and doctors. At a meeting in Atlanta, the panel approved a half-measure that says older teens and young adults may get the shots— if they and their parents want to take that step.

  • *Fast-track legislation clears Senate procedural hurdle. *Senate vote of 60-37 shows solid support base. On Wednesday, the Senate was likely to vote to grant Obama the power to speed trade deals through Congress, including his Trans-Pacific Partnership.

  • Two big problems with generic-drug substitution Tuesday, 23 Jun 2015 | 3:54 PM ET
    Pharmaceutical drugs

    Automatic generic-drug substitution poses several big problems, says NYU Professor Melissa Schilling.

  • Senate vote of 60-37 shows solid support base. WASHINGTON, June 23- President Barack Obama's quest for a Pacific Rim trade deal to strengthen U.S. ties with Asia advanced on Tuesday, with the Senate moving toward a final vote on granting Obama the power to speed trade agreements through Congress. That just barely satisfied the 60- vote threshold needed after two...

  • *Senate vote 60-37 shows solid support base. WASHINGTON, June 23- President Barack Obama's Pacific Rim trade pact moved closer to a final U.S. Congress vote, with lawmakers agreeing on Tuesday to limit debate on legislation that would grant Obama authority to speed trade deals through Congress. A Senate vote on the legislation, known as fast-track negotiating...

  • Uncertainty for stocks remains. What to buy Tuesday, 23 Jun 2015 | 8:00 AM ET
    Traders work on the floor of the New York Stock Exchange.

    U.S. stocks could be in for a bumpy ride this summer as concerns over Greece's debt situation mount. Here's how to play it.

  • President Barack Obama' s signature Pacific trade pact faces another test in the Senate on Tuesday as legislation needed to close the deal returns for a second run through the chamber. Although the measure passed the Senate a month ago on a vote of 62-37, including backing from 14 Democrats, some may withdraw support. It took two attempts to pass this same...

  • Early movers: CI, WMB, PFE, ALL, AAPL & more Monday, 22 Jun 2015 | 7:47 AM ET
    Traders work on the floor of the New York Stock Exchange (NYSE).

    Some of the names on the move ahead of the open.

  • LONDON, June 22- GlaxoSmithKline has agreed to sell two meningitis vaccines to Pfizer to satisfy antitrust concerns after its recent acquisition of vaccines business of Novartis. The British drugmaker said on Monday that the total consideration for the sale of its Nimenrix and Mencevax products to Pfizer's Irish unit, including some deferred payments, was...

  • Early movers: FDX, KYTH, HRC, PFE, LLY & more Wednesday, 17 Jun 2015 | 7:54 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Traders work on the floor of the New York Stock Exchange.

    U.S. stocks closed higher as the Fed began its two-day meeting and investors attempted to shake off worries about the Greece debt talks.

  • Dollar's rampage costs companies billions: Study Monday, 15 Jun 2015 | 6:00 AM ET
    Sheets of one dollar bills run through the printing press at the Bureau of Engraving and Printing in Washington, DC.

    The market knew it would be ugly. Now, it's clear just how much havoc the strong dollar is wreaking on corporate America.

  • Wall Street firm's portfolio up 29% in 18 months Friday, 12 Jun 2015 | 2:46 PM ET
    Trader on the floor of the New York Stock Exchange.

    A portfolio by investment bank Jefferies is up 29 percent since it was created in December 2013. Here are some of the stocks...

  • Stocks that may break out while market drags Friday, 12 Jun 2015 | 11:48 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Traders are finding shorter-term opportunities amidst market drag.

  • Asian shares mostly rise on a quiet Friday, with China's Shanghai Composite index edging up to its highest close since January 2008.

  • Cramer: Massive biotech moves that make sense Thursday, 11 Jun 2015 | 6:57 PM ET
    A worker prepares a flow cell slide for a genetic sequencing machine at a Regeneron Pharmaceuticals laboratory company's headquarters in Tarrytown, New York.

    Jim Cramer discusses the huge moves that the biotech stocks have made recently—do these moves make sense for your portfolio?